Monday, October 18, 2010

NAMA Recovery Announces Two More Directors to Join the Board: Lisa Mojer-Torres Esq and Nanette Wollfarth CMA

National Alliance for Medication Assisted Recovery
Press Release

Contact Persons
:
Roxanne Baker, President, president@methadone.org
Joycelyn Woods, Executive Director, edirector@methadone.org
Phone/Fax: 212-595-NAMA



 
It is with great pleasure that NAMA Recovery announces the addition of two additional new board members Lisa Mojer Torres and Nanette Wollfarth. Like our other recent additions to the Board they bring with them years of experience working in advocacy and making treatment and recovery a reality for thousands. Lisa Torres recipient of this years’ Richard Lane/Robert Holden Advocacy Award has served the NAMA Recovery Board twice before with her legal skills. Nanette Wollfarth is the Chapter Coordinator and brings her knowledge of national and international issues.


This brings the current Board of Directors to:

Roxanne Baker, C.M.A., President
Donna Schoen, C.M.A., Vice President
Kerry Wolf, B.S.N., C.M.A , 2nd Vice President
Jo Sotheran, Ph.D., C.M.A., Treasurer and Secretary

J.R. Neuberger, C.M.A. Parliamentarian and Newsletter Editor
Chris Kelly, Advocates for Recovery though Medicine
Ira Marion, M.A.
Lisa Mojer Torres, Esq
Nanette Wollfarth, C.M.A., Chapter Coordinator

Friday, October 15, 2010

MARS Project Receives Funding for Another Four Years

National Alliance for Medication Assisted Recovery
Press Release

Contact Persons
:
Roxanne Baker, President, president@methadone.org
Joycelyn Woods, Executive Director, edirector@methadone.org
Walter Ginter, MARS Project Director, matrecovery@methadone.org
Phone/Fax: 212-595-NAMA


The MARS Project (Medication Assisted Recovery Services) the only Peer to Peer Recovery Services Center has received a second grant to continue the project. It is a proud moment for NAMA Recovery because over 220 proposals were submitted and only 5 grants awarded. It is confirmation that a small patient run organization can compete with the big guys and win. The proposal was also the only one to receive continuous funding.

The MARS Project is a new way of thinking for providers and patients of Medication Assisted Treatment (MAT). It is not a part of the program but instead works alongside programs and is managed entirely by patients for patients to have a safe and supportive place to go to. NAMA Recovery has learned that patients want information and to learn about their medication, addiction and regulations. Peers at MARS receive the Core Training that consists of (1) Advanced Addiction that covers psychopharmacology, neuroscience, biochemistry and addiction science, the (2) Education Series deals with many diverse issues from history of methadone to confidentiality and (3) Recovery completes the series since it is a new concept for most patients.

Unlike many recovery centers MARS is not a place to house 12 step meetings. There is only one weekly 12 step meeting and another group on spirituality and recovery. Most of the groups change over time as peers find new interests. Some groups are for socialization and fun like the Book Club and Arts and Crafts while others are discussion groups like Women’s or Men’s Issues and some groups cover practical topics like Taking Care of Your Heath and Relapse Prevention.

Monday, September 27, 2010

NAMA Recovery Announces Two New Directors to Join the Board: Chris Kelly and Ira Marion

National Alliance for Medication Assisted Recovery
Press Release

Contact Persons:
Roxanne Baker, President, president@methadone.org
Joycelyn Woods, Executive Director, edirector@methadone.org
Phone/Fax: 212-595-NAMA

For Release:
September 26, 2010


NAMA Recovery Announces Two New Directors to Join the Board:
Chris Kelly and Ira Marion



It is with great pleasure that NAMA Recovery announces the addition of two new board members Chris Kelly of Advocates for Recovery through Medication and Ira Marion of Albert Einstein College of Medicine. Both bring with them years of experience working in advocacy and making treatment and recovery a reality for thousands.

This brings the current Board of Directors to:

Roxanne Baker, C.M.A., President
Donna Schoen, C.M.A., Vice President
Kerry Wolf, B.S.N., C.M.A , 2nd Vice President
Jo Sotheran, Ph.D., C.M.A., Treasurer and Secretary

Barbara Finger, C.M.A.
J.R. Neuberger, C.M.A. Parliamentarian and Newsletter Editor
Chris Kelly
Ira Marion, M.A.

Administration
Joycelyn Woods, M.A., C.M.A. Executive Director
Nanette C. Wollfarth, C.M.A., Chapter Coordinator Claude Hopkins, R.M.A., C.M.A., Grievance/Compliment Coordinator Herman Joseph, Ph.D., C.M.A., Ambassador At Large Norma Alexander, C.M.A., Publicity and Special Events Coordinator
Walter Ginter, C.M.A., Director of Training & Recovery Services & MARS Project

Monday, July 26, 2010

Methadone Under Attack in Pennsylvania Voice Your Opposition to Pennsylvania’s Methadone Accountability Package


National Alliance for Medication Assisted Recovery
Press Release


Contact Persons:
Joycelyn Woods, Executive Director, edirector@methadone.org
Roxanne Baker, President, president@methadone.org
Phone/Fax: 212-595-NAMA

Ericka Lear PA NAMA 814-695-1014

For Release:
July 26, 2010



Methadone Under Attack in Pennsylvania Voice Your Opposition
to Pennsylvania’s Methadone Accountability Package



In May Pennsylvania legislators announced at a press conference a number of bills that would be introduced. They claim that the intent is to increase safety, fiscal accountability and reduce the use of illicit methadone in an effort to reduce methadone overdose deaths the legislation is based on prejudice and ignorance. Methadone treatment is already strictly regulated at both the federal and state levels more than any medication or medical treatment. Nevertheless as in the past opioid treatment programs are the focus.
Here is what the legislation would do:

- Patients would need a designated driver when starting methadone or increasing dosage and get tested more often for other drugs that in combination with methadone impair driving.
Response: Numerous studies have reported that stable patients can perform as well as any non methadone patient driver. Federal and state regulations already require toxicology tests that are sufficient.

- Driving with more than the prescribed dose of methadone would constitute driving under the influence, and driving with methadone in combination with alcohol or other drugs would constitute "high-impairment" DUI.
Response: How would one determine if a patient has taken more than their required dose? There is no way.

- Methadone clinics must be open seven days a week - up from six - to curtail selling of "take home" doses.
Response: This is an unnecessary expense and should be decided and based on each individual OTPs needs.

- Clinics must give all startup patients an opioid antagonist drug The Antagonist Challenge Test.
Response: This is a barbaric practice that was used by a few states over thirty years ago. It is dangerous and most certainly will result in deaths.

- Clinics must test for a certain type of sedative and dispense methadone to patients only if a psychiatrist attests to its necessity.
Response: This is already a federal requirement and unnecessary.

- Patients couldn't take home doses for six months - up from three.
Response: Take home doses should be based on a patient’s responsibility and both the federal government and state have requirements that patients must meet which are quite rigid.

- The industry would need to create protocols to determine when patients are no longer benefiting methadone and clinics would discharge these patients.
Response: All patients benefit or they would leave.

- Patients would have funding for one year.
Response: Excellent if this applies to all patients encouraging persons to enter treatment.

- Patients would need to patronize the nearest clinic, to reduce alleged abuse of transportation subsidies.
Response: Most patients already do this.

- The state's methadone support system would be audited.
Response: The state already inspects, licenses OTP and responds to complaints in addition to SAMHSA accreditation and licensing and DEA requirements.

- The state would create a Methadone Death Review Team to gather data and figure out how to reduce the number of fatalities.
Response: NAMA Recovery would be in support of this. The team should include professionals, policy makers and patient advocates. Standards need to be developed about what constitutes a methadone death and those in combination with other substances.

- The state would develop screening standards for methadone candidates.
Response: The federal government and state already have requirements.

- The state would standardize intake procedures, warn potential patients of the risk and advise them of alternative strategies.
Response: The federal government and state have standard intake procedures.

- Treatment plans would lay out a schedule for getting off methadone within two years, unless there's good reason.
Response: Treatment plans should be focused on recovery getting one’s life together not a schedule to get off.

- Patients would get a minimum two hours counseling per week.
Response: OTP caseloads are greater than other types of addiction treatment. Counseling needs to be on using a who needs it basis. Forced counseling requirements diverts the counselors attention from patients that need their time thus insuring that nobody gets what they need. A counselor with the standard 50 patient caseload would have to work 100 hours a week.

- Clinics would screen patients for other drugs at the start and every two weeks.
Response: Regular screening is already part of the federal and state regulations. Every two weeks is costly and unnecessary.

- Patients couldn't drive for the first two weeks - or a month, if they test positive for other drugs.
Response: This would mean that no patients could not drive for the first 2 weeks since they must test positive for drugs at admission.

- Clinics must develop plans to curtail illicit sale of methadone by patients.
Response: The federal regulations already require this of each program as well as most states.

- Patients may take home doses only if it's consistent with a treatment plan, there's minimal risk of abuse, it would help in treatment and the client hasn't abused take home previously.
Response: Actually federal and state requirements already require this and including an additional 6 requirements.

- Programs could discharge patients who sell doses or who threaten or commit violence.
Response: These are the two reasons that programs already administratively discharge patients.

Sources: State Sens. John H. Eichelberger Jr., R-Blair, Mike Stack, D-Philadelphia, and Kim Ward, R-Westmoreland.

Methadone maintenance treatment has been thoroughly researched and carefully evaluated for over four decades. It has received more scientific scrutiny and evaluation than any other medical treatment or human service program. Most evaluations have shown that, when correctly implemented, the treatment is capable of producing remarkable improvements in patients who were previously dysfunctional heroin addicts. Methadone maintenance patients throughout the world have been restored to productive lives, relations with families and children have been reestablished, many have furthered their educations, obtained employment and improved their physical and mental health. Nevertheless, contrary to scientific evidence, methadone maintenance treatment remains a controversial issue among substance abuse treatment providers, public officials and policy makers, the public at large and the medical profession itself.

Download the following:

Copy of this press release
Letters sent by NAMA Recovery
Announcement the Methadone Accountability Package
What Can You Do? and Sample Letter
List of Pennsylvania's House Represenataives & Addresses
List of Pennsylvania's Senators & Addresses

Sign the Petition Opposing the Methadone Accountability Package

Saturday, February 27, 2010

Help Identify What Patients Do To Make Recovery Work

February 28, 2010

Stabilized patients who have been in methadone maintenance for more than one year (with negative urinalysis tests for all illicit substances except methadone).

Have you ever considered your status as a long term methadone patient, AKA elite methadone patient to be an achievement worth celebrating? I do and so do many others. And, it is! One problem is that fewer patients remain in methadone maintenance for longer periods of time. It took me several episodes of treatment before I began to understand and distinguish the differences in value between the medication (methadone); the modality (methadone maintenance); and the way methadone is dispensed (the methadone program or clinic system). So, I became an advocate for better and more information to patients about how methadone maintenance works and involved on several levels in improving the way methadone is dispensed; the clinic system.

About me:

My name is Lisa Mojer-Torres and I have been a patient for 20 years. I tried to withdraw from methadone maintenance three or four times before learning about its pharmacology. Since stabilizing on my optimal dose, I have become a practicing attorney, (admitted in NY and NJ) and an advocate for methadone maintenance as a modality and methadone patients as victims of stigma and discrimination. I have a life that includes rewarding employment, a beautiful family, and our own home.

This project:

Currently, I am writing an article with leading recovery expert that analyzes methadone maintenance as a legitimate path into and through “recovery” from active addiction to heroin and other opioids. There are several uses for methadone and even different stages within methadone maintenance pharmacotherapy. However, once a patient and his/her doctor identify the patient’s optimal dose of methadone (the particular dose that affords the patient the maximum benefits methadone offers in managing the chronic disease of opioid addiction), the patient remains on that dose with the exception of a rare taper. The patient has achieved “optimal dose stabilization”. Without the distractions of withdrawal symptoms, or the obsessive cravings for opioids (and an opioid blockade as well) the patient is in the strongest position to leave the life of active opioid addiction behind, transitioning from treatment to recovery. It is this transition that I am interested in documenting.

Why I am reaching out to you:

In order to document the transition from treatment to recovery, I believe it is imperative to go directly to the source and seek information from those patients who’ve succeeded with methadone maintenance about how they succeeded. I am also interested in learning what resources would have made your experience easier. I am interested in learning what and whether you think achieving optimal dose stabilization has played any role in your life and/or the lives of other patients. The three-part article will conclude with a statement that opioid addicts who achieve optimal dose stabilization with methadone are on an equal par to alcoholics who stop drinking and others who stop using, etc. Mostly, I am interested in learning the various skills you used in overcoming ignorance about methadone and how you managed to sustain recovery.

Confidentiality:

I don’t need to know your name or any other identifying information for this project. At any rate I am restricted by confidentiality laws. Your treatment program was kind enough to cooperate in allowing this notice to be posted in the OTP, but no one is under any obligation to respond. However, unless and until the public becomes aware that there is a significant population of stabilized in methadone maintenance patients in recovery, we will continue to be defined by those still struggling with active addiction. I would be grateful if you would spare a few moments of your time to participate in this anecdotal survey. I promise your time and effort will not be wasted and I will do my best to create a resource that speaks directly to the current generation of opioid addicts who, still stuck in the grips of active addiction have not been unable to maximize methadone’s full potential. It’s my hope that by offering to share our experiential jewels of information, others will believe a life in recovery is possible, even for them.

IF YOU ARE WILLING TO PARTICIPATE IN AN E-MAIL EXCHANGE OR A PHONE INTERVIEW, PLEASE CONTACT ME, Lisa Mojer-Torres VIA E-MAIL @ rtorres605@aol.com OR TELEPHONE at my home/office @ (609) 671-1995 either 7AM-9AM weekday mornings or 7PM-9PM weekday eves. (I work during the day). Call any time over the weekend; I will do my best to hang around the house over the next couple of weekends. But, in the event you reach our voice mail, PLEASE either leave a message providing instructions about how to reach you OR call me back. My goal is to complete interviews by March 7th, latest, so please try and act upon this ASAP. If you wait, we all lose.

Sincerely,

Lisa Mojer-Torres (Using Google, you can check out more information about my advocacy efforts on the national level)
Email: RTORRES605@AOL.COM
Telephone: (609) 608 671-1995
.

Monday, February 15, 2010

Howard Stephen Lotsof (3/1/1943 - 1/31/2010)

National Alliance for Medication Assisted Recovery
Press Release


Contact Persons:
Joycelyn Woods, Executive Director, edirector@methadone.org
Roxanne Baker, President, president@methadone.org
Phone/Fax: 212-595-NAMA

For Release:
February 15, 2010



Howard Stephen Lotsof (3/1/1943 - 1/31/2010)

It is with great sadness that NAMA Recovery announces the passing of our long time board member and fellow advocate Howard Lotsof. He passed away Sunday, January 31, 1010 at 6 PM in Staten Island University Hospital.

Howard was an important part of NAMA Recovery and methadone advocacy. He came to us because of his experience in developing Ibogaine and having to work with methadone programs. They had sure changed since he was a patient many years before. He believed that treatment should be a positive experience and so in typical Howard fashion he could not hold himself back to set things right. He helped a lot of people with issues and problems that they had during the years that he was with NAMA Recovery and his presence will be greatly missed.

But Howard also had another life as an Ibogaine advocate. He single handed -- as a citizen with no background in drug development -- convinced the National Institute of Drug Abuse (NIDA) to provide funding for Ibogaine studies in the US. Only large pharmaceutical companies have the resources to accomplish this -- and of course Howard Lotsof.

The funeral was Friday, February 5, 1010 at Harmon Funeral Home in Staten Island. He will be intered at the Fairview Cemetery, 1852 Victory Blvd., Staten Island.

He was a nobel and inspiring man and we send Norma and his family our most heartfelt sympathy on his passing. We will miss him very much.

Note: His wife Norma Lotsof is asking for assistance for the gravestone. Donations can be sent to: Ms. Norma Lotsof, 46 Oxford Place, Staten Island, NY 10301



Obituary
Howard S. Lotsof, 66, discoverer of the anti-addictive effect of ibogaine, died of liver cancer on Sunday January 31, 2010 in Staten Island.
Mr. Lotsof was the first individual to observe the effect of ibogaine, a naturally occurring plant alkaloid with a history of use as a ritual hallucinogen in Africa, in detoxification from heroin. He subsequently originated patents for the use of ibogaine in treating addictions, including opioids, cocaine and amphetamine, alcohol, and nicotine.
Mr. Lotsof’s work initiated substantial research into ibogaine and related compounds in the mainstream scientific community. He provided pilot data to the National Institute on Drug Abuse that became the basis for a program of research on ibogaine that generated scores of peer-reviewed publications and led to the approval by the US Food and Drug Administration of a Phase 1 clinical trial. Beginning with research funding provided by Mr. Lotsof 25 years ago, Stanley D. Glick, M.D., Ph.D., Professor and Director of the Center for Neuropharmacology and Neuroscience Albany Medical College, has produced a body of work on ibogaine and related compounds that presently includes over 60 peer-reviewed publications and has been supported for more than two decades by the National Institutes of Health. Mr. Lotsof himself authored or coauthored scientific papers on ibogaine in respected academic publishing venues such as the Journal of Ethnopharmacology and the American Journal on Addictions. These accomplishments are all the more extraordinary in view of the fact that Mr. Lotsof, a graduate of NYU who majored in film was without a doctoral level degree.
The FDA-approved clinical study was never completed due to contractual disputes, which was Mr. Lotsof’s deepest professional disappointment. Nonetheless, an expanding global context of ibogaine use for the treatment of addiction continues to exist in medical and non-medical settings across the world, and ibogaine continues to be studied as a paradigm for fundamental research and the development of new treatment for addiction.
Mr. Lotsof is survived by his wife, Norma, and two sisters Rosalie Falato and Holly Weiland.

Nominations Open for the Richard Lane/Robert Holden Methadone Advocacy Award

National Alliance for Medication Assisted Recovery
Press Release


Contact Persons:
Joycelyn Woods, Executive Director, edirector@methadone.org
Roxanne Baker, President, president@methadone.org
Phone/Fax: 212-595-NAMA


For Release:
February 15, 2010



Nominations Open for the Richard Lane/Robert Holden Methadone Advocacy Award


Richard Lane was a long-term heroin user who, upon release from prison in 1967, was instrumental in establishing one of the Nation’s first methadone treatment programs. In 1974, he became the Executive Director of Man Alive and later served as Vice President of the American Methadone Treatment Association and as Vice Chairman of the Governor’s Council on Alcohol and Drug Abuse in Maryland. Mr. Lane was a passionate advocate for methadone treatment and, by disclosing his own treatment experiences, provided inspiration to patients and colleagues alike.

Robert Holden was also a recovering heroin user, who later became the Director of PIDARC, an outpatient methadone treatment program in the District of Columbia. He was a friend of Richard Lane and succeeded Richard Lane’s term of office as the Vice President of the American Association for the Treatment of Opioid Dependence. This award was established in 1995 and recognizes extraordinary achievements in patient advocacy.

The following criteria should be applied in making your selection:

  • Only one (1) nominee can be submitted to the Conference Awards Committee. There may be a number of nominees, however only one (1) “consensus” nominee may receive this honor.
  • The nominee must have been involved in the field of methadone advocacy for a period of five (5) years.
  • The nominee must have been actively engaged in methadone advocacy for a period of five (5) years.
  • The nominee must have made meaningful and consistent contributions, which have had a significant impact on opioid treatment within a state or region of the United States.
  • For each nominee a Nomination Form must be completed and submitted with two (2) Letters of Support. The Nomination Form is attached to this announcement and can also be downloaded from the NAMA Recovery website http://www.methadone.org/.
  • Additional information about the award can be found at the NAMA Recovery website http://www.methadone.org/richard_lane.html.
  • NAMA Recovery will be responsible for collecting all the submissions for nomination, selecting a committee of advocates that will decide on the final candidate. The Candidate’s Name, Nomination Form and at least two (2) Letters of Support describing the nominee’s achievements will be submitted to the Awards Committee for the final approval.
  • The Deadline for Submission is February 26, 2010. The completed Nomination Form along with at least two (2) Letters of Support should be sent to Joycelyn Woods at edirector@methadone.org.

Previous Winners of the Award

2001, St. Louis Joycelyn Woods

2007, Atlanta Anthony Scro

2009, New York Walter Ginter

This Award will be bestowed upon the recipient during the Awards Banquet Ceremony of October 26,2010 during AATOD's next National Conference which will convene in Chicago at the Hilton Hotel.

The recipient will be provided with a roundtrip Coach Class airfare in addition to up to two (2) nights in the hotel. The individual will also be able to attend the Conference.


Deadline: Wednesday, February 26, 2010
Email Nominations To: edirector@methadone.org
Joycelyn Woods

If you have any questions about the award contact Joycelyn Woods at edirector@methadone.org or by telephone at (718) 993-3397.